4 ms·

23andMe is exploring splitting the DNA company in two

12 points by mfiguiere 3y ago

toomuchtodo 3y ago
https://archive.today/dLu1M https://archive.today/dLu1M
bradly 3y ago
Why sell off your customer's DNA once when you can sell it off twice?
cortesoft 3y ago
So... mitosis?
- nonrandomstring 3y ago
  What about your toes?
AlbertCory 3y ago
> Wojcicki said one of the challenges is how to get customers spend for new products, like blood testing. I can believe that some cancers could be detected early via nucleotides found in the blood. However, Elizabeth Holmes might like a word here. Testing people's blood is a highly regulated activity. One does not simply jump into it.
- nradov 3y ago
  There are already several companies selling liquid biopsy tests for early stage cancer screening. Basically they look for cell-free DNA containing mutations highly correlated with cancer. Galleri is probably the biggest player in this space. https://www.galleri.com/ https://www.galleri.com/
  - AlbertCory 3y ago
    it says "In a clinical study, around 4 out of 10 people with this result were diagnosed with cancer after diagnostic testing." so is my arithmetic correct, in that it's a 60% false positive rate?
    - dekhn 3y ago
      That corresponds to the publication, https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01700-2/fulltext?rss=yes https://www.thelancet.com/journals/lancet/article/PIIS0140-6... "A cancer signal was detected in 92 (1·4%) of 6621 participants with analysable results. 35 (38%) participants were diagnosed with cancer (true positives) and 57 (62%) had no cancer diagnosis (false positives)." I am surprised that they were approved based on their study results, it will be interesting to see the results from PATHFINDER 2, which is running now.
      - nradov 3y ago
        If there a legal reason that the test shouldn't be approved? Although the false positive rate is high, it's ultimately up to the patient and their doctor about whether to order the test and what to do with the results. I do understand the concerns over false positives unnecessarily scaring patients and leading to wasteful additional diagnostic tests, but I don't think the FDA really accounts for that in the approval process. Detecting early stage cancer in a liquid biopsy is extremely difficult so it's impressive that they made it work at all.
        dekhn 3y ago
        It's policy not law (the law give the FDA authority to set policy and makes decisions). And they definitely would consider the sensitivity and specificity and PPV of a test. TBH it's amazing it got approved. But the product leadership and founding team definitely knew how to play the FDA game. Yes, early cancer tests are fantastic. However, tests need to have extremely good sensitivity and specificity for exactly the reason you said.
    - 3y ago
michael1999 3y ago
If I'm not interested in watching 23andMe flail trying to sell personal health info, does anyone have a recommendation for private whole-genome sequencing? I found Nebula at $550. Is there anywhere else people can recommend where I keep ownership?
Thaxll 3y ago
So that company is on the verge of bankruptcy but their CEO got a 32$M payout last year?
- voisin 3y ago
  As the prophesies foretold, doom shall not impede a healthy executive bonus.
psunavy03 3y ago
So the DNA company is becoming RNA?
- voisin 3y ago
  Either that or it becomes CH11
pvaldes 3y ago
Is ElevenAndYourLawyer registered?
JohnFen 3y ago
They already completely burned any trust I had in them. If they split into two companies, that will just be two companies that I wouldn't trust with anything.
klipklop 3y ago
23andMe has always been a shady company. It would be better for them to go out of business and all the data they collected on people be deleted. Of course they are looking for new ways to bypass any privacy laws to share peoples genetic info to the highest bidder. Everyone I know regrets sending off their DNA to them for ancestry parlor tricks and other non-relevant information.
vidanay 3y ago
Meiosis or Mitosis?

12 points by mfiguiere 3y ago

toomuchtodo 3y ago

https://archive.today/dLu1M https://archive.today/dLu1M

bradly 3y ago

Why sell off your customer's DNA once when you can sell it off twice?

cortesoft 3y ago

So... mitosis?

nonrandomstring 3y ago
What about your toes?

AlbertCory 3y ago

> Wojcicki said one of the challenges is how to get customers spend for new products, like blood testing. I can believe that some cancers could be detected early via nucleotides found in the blood. However, Elizabeth Holmes might like a word here. Testing people's blood is a highly regulated activity. One does not simply jump into it.

nradov 3y ago
There are already several companies selling liquid biopsy tests for early stage cancer screening. Basically they look for cell-free DNA containing mutations highly correlated with cancer. Galleri is probably the biggest player in this space. https://www.galleri.com/ https://www.galleri.com/
- AlbertCory 3y ago
  it says "In a clinical study, around 4 out of 10 people with this result were diagnosed with cancer after diagnostic testing." so is my arithmetic correct, in that it's a 60% false positive rate?
  - dekhn 3y ago
    That corresponds to the publication, https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01700-2/fulltext?rss=yes https://www.thelancet.com/journals/lancet/article/PIIS0140-6... "A cancer signal was detected in 92 (1·4%) of 6621 participants with analysable results. 35 (38%) participants were diagnosed with cancer (true positives) and 57 (62%) had no cancer diagnosis (false positives)." I am surprised that they were approved based on their study results, it will be interesting to see the results from PATHFINDER 2, which is running now.
    - nradov 3y ago
      If there a legal reason that the test shouldn't be approved? Although the false positive rate is high, it's ultimately up to the patient and their doctor about whether to order the test and what to do with the results. I do understand the concerns over false positives unnecessarily scaring patients and leading to wasteful additional diagnostic tests, but I don't think the FDA really accounts for that in the approval process. Detecting early stage cancer in a liquid biopsy is extremely difficult so it's impressive that they made it work at all.
      - dekhn 3y ago
        It's policy not law (the law give the FDA authority to set policy and makes decisions). And they definitely would consider the sensitivity and specificity and PPV of a test. TBH it's amazing it got approved. But the product leadership and founding team definitely knew how to play the FDA game. Yes, early cancer tests are fantastic. However, tests need to have extremely good sensitivity and specificity for exactly the reason you said.
  - 3y ago

michael1999 3y ago

If I'm not interested in watching 23andMe flail trying to sell personal health info, does anyone have a recommendation for private whole-genome sequencing? I found Nebula at $550. Is there anywhere else people can recommend where I keep ownership?

Thaxll 3y ago

So that company is on the verge of bankruptcy but their CEO got a 32$M payout last year?

voisin 3y ago
As the prophesies foretold, doom shall not impede a healthy executive bonus.

psunavy03 3y ago

So the DNA company is becoming RNA?

voisin 3y ago
Either that or it becomes CH11

pvaldes 3y ago

Is ElevenAndYourLawyer registered?

JohnFen 3y ago

They already completely burned any trust I had in them. If they split into two companies, that will just be two companies that I wouldn't trust with anything.

klipklop 3y ago

23andMe has always been a shady company. It would be better for them to go out of business and all the data they collected on people be deleted. Of course they are looking for new ways to bypass any privacy laws to share peoples genetic info to the highest bidder. Everyone I know regrets sending off their DNA to them for ancestry parlor tricks and other non-relevant information.

vidanay 3y ago

Meiosis or Mitosis?